TY - JOUR
T1 - Treatment and survival of rectal cancer patients over the age of 80 years
T2 - a EURECCA international comparison
AU - Claassen, Yvette H. M.
AU - Vermeer, Nina C. A.
AU - Iversen, Lene H.
AU - van Eycken, Elizabeth
AU - Guren, Marianne G.
AU - Mroczkowski, Pawel
AU - Martling, Anna
AU - Cazador, Antonio
AU - Johansson, Robert
AU - Vandendael, Tamara
AU - Wibe, Arne
AU - Moller, Bjorn
AU - Lippert, Hans
AU - Rutten, Harm J. T.
AU - Portielje, Johanneke E. A.
AU - Liefers, Gerrit J.
AU - Holman, Fabian A.
AU - van de Velde, Cornelis J. H.
AU - Bastiaannet, Esther
PY - 2018/8/14
Y1 - 2018/8/14
N2 - BACKGROUND: The optimal treatment strategy for older rectal cancer patients remains unclear. The current study aimed to compare treatment and survival of rectal cancer patients aged 80+. METHODS: Patients of >= 80 years diagnosed with rectal cancer between 2001 and 2010 were included. Population-based cohorts from Belgium (BE), Denmark (DK), the Netherlands (NL), Norway (NO) and Sweden (SE) were compared side by side for neighbouring countries on treatment strategy and 5-year relative survival (RS), adjusted for sex and age. Analyses were performed separately for stage I-III patients and stage IV patients. RESULTS: Overall, 19 634 rectal cancer patients were included. For stage I-III patients, 5-year RS varied from 61.7% in BE to 72.3% in SE. Proportion of preoperative radiotherapy ranged between 7.9% in NO and 28.9% in SE. For stage IV patients, 5-year RS differed from 2.8% in NL to 5.6% in BE. Rate of patients undergoing surgery varied from 22.2% in DK to 40.8% in NO. CONCLUSIONS: Substantial variation was observed in the 5-year relative survival between European countries for rectal cancer patients aged 80+, next to a wide variation in treatment, especially in the use of preoperative radiotherapy in stage I-III patients and in the rate of patients undergoing surgery in stage IV patients.
AB - BACKGROUND: The optimal treatment strategy for older rectal cancer patients remains unclear. The current study aimed to compare treatment and survival of rectal cancer patients aged 80+. METHODS: Patients of >= 80 years diagnosed with rectal cancer between 2001 and 2010 were included. Population-based cohorts from Belgium (BE), Denmark (DK), the Netherlands (NL), Norway (NO) and Sweden (SE) were compared side by side for neighbouring countries on treatment strategy and 5-year relative survival (RS), adjusted for sex and age. Analyses were performed separately for stage I-III patients and stage IV patients. RESULTS: Overall, 19 634 rectal cancer patients were included. For stage I-III patients, 5-year RS varied from 61.7% in BE to 72.3% in SE. Proportion of preoperative radiotherapy ranged between 7.9% in NO and 28.9% in SE. For stage IV patients, 5-year RS differed from 2.8% in NL to 5.6% in BE. Rate of patients undergoing surgery varied from 22.2% in DK to 40.8% in NO. CONCLUSIONS: Substantial variation was observed in the 5-year relative survival between European countries for rectal cancer patients aged 80+, next to a wide variation in treatment, especially in the use of preoperative radiotherapy in stage I-III patients and in the rate of patients undergoing surgery in stage IV patients.
KW - IV COLORECTAL-CANCER
KW - ELDERLY-PATIENTS
KW - PREOPERATIVE RADIOTHERAPY
KW - DELAYED SURGERY
KW - OLDER PATIENTS
KW - PRIMARY TUMOR
KW - FOLLOW-UP
KW - COUNTRIES
KW - RESECTION
KW - CHEMORADIOTHERAPY
U2 - 10.1038/s41416-018-0215-6
DO - 10.1038/s41416-018-0215-6
M3 - Article
C2 - 30057408
SN - 0007-0920
VL - 119
SP - 517
EP - 522
JO - British Journal of Cancer
JF - British Journal of Cancer
IS - 4
ER -